Acura Pharmaceuticals (ACUR): Price and Financial Metrics


Acura Pharmaceuticals (ACUR): $0.53

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACUR Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ACUR is 16.63 -- better than 98.25% of US stocks.
  • With a year-over-year growth in debt of -94.83%, Acura Pharmaceuticals Inc's debt growth rate surpasses only 1.94% of about US stocks.
  • Revenue growth over the past 12 months for Acura Pharmaceuticals Inc comes in at -44.87%, a number that bests only 3.61% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Acura Pharmaceuticals Inc are ADXS, ALV, OCFT, GILT, and NEU.
  • Visit ACUR's SEC page to see the company's official filings. To visit the company's web site, go to www.acurapharm.com.

ACUR Valuation Summary

  • In comparison to the median Healthcare stock, ACUR's EV/EBIT ratio is 216.04% lower, now standing at -34.
  • ACUR's price/sales ratio has moved up 14 over the prior 243 months.
  • ACUR's price/sales ratio has moved up 14 over the prior 243 months.

Below are key valuation metrics over time for ACUR.

Stock Date P/S P/B P/E EV/EBIT
ACUR 2021-08-31 16.1 100.5 -24.5 -34.0
ACUR 2021-08-30 15.0 93.7 -22.8 -31.7
ACUR 2021-08-27 16.1 100.5 -24.5 -34.0
ACUR 2021-08-26 14.7 91.9 -22.4 -31.1
ACUR 2021-08-25 13.7 85.3 -20.8 -28.9
ACUR 2021-08-24 15.0 93.7 -22.8 -31.7

ACUR Growth Metrics

    Its 4 year price growth rate is now at -88.99%.
  • Its 3 year net cashflow from operations growth rate is now at 57.03%.
  • Its 5 year net cashflow from operations growth rate is now at 101.65%.
ACUR's revenue has moved down $4,412,000 over the prior 49 months.

The table below shows ACUR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 2.245 -0.396 -1.151
2021-06-30 2.385 -1.132 -1.567
2021-03-31 3.123 -1.379 -0.872
2020-12-31 3.57 -0.719 -1.208
2020-09-30 4.072 -0.117 -0.81
2020-06-30 4.986 1.028 0.068

ACUR Stock Price Chart Interactive Chart >

Price chart for ACUR

ACUR Price/Volume Stats

Current price $0.53 52-week high $0.75
Prev. close $0.53 52-week low $0.29
Day low $0.49 Volume 1,000
Day high $0.53 Avg. volume 7,230
50-day MA $0.45 Dividend yield N/A
200-day MA $0.52 Market Cap 34.66M

Acura Pharmaceuticals (ACUR) Company Bio


Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.


ACUR Latest News Stream


Event/Time News Detail
Loading, please wait...

ACUR Latest Social Stream


Loading social stream, please wait...

View Full ACUR Social Stream

Latest ACUR News From Around the Web

Below are the latest news stories about Acura Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACUR as an investment opportunity.

Acura, Abuse Deterrent Pharmaceuticals amend license deal for pain drug LIMITx LTX-03

Acura Pharmaceuticals (ACUR) amended a license, development and commercialization agreement for its product candidate LIMITx LTX-03 with Abuse Deterrent Pharmaceuticals to extend the…

Seeking Alpha | March 1, 2022

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03

Amendment Extends NDA Acceptance DatePALATINE, Ill., March 01, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to December 31, 2022. The Company expects to complete clinical studies and other required s

Yahoo | March 1, 2022

Acura Pharmaceuticals Provides Development Update on LTX-03

PALATINE, Ill., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx technology manufactured in the three New Drug Application (“NDA”) required registration batches successfully passed testing at the six month time point in an ongoing shelf life study when stored at normal temperature and humidity conditions, also known as controlled room temperature (“CRT”). The patente

Yahoo | February 14, 2022

Acura Pharmaceuticals (OTCMKTS:ACUR) Shares Pass Above 200 Day Moving Average of $0.55

Shares of Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.55 and traded as high as $0.55. Acura Pharmaceuticals shares last traded at $0.55, with a volume of 2,404 shares traded. The company has a quick ratio of 0.86, a []

Dakota Financial News | December 11, 2021

Acura Pharmaceuticals reports Q3 results

No summary available.

Seeking Alpha | November 15, 2021

Read More 'ACUR' Stories Here

ACUR Price Returns

1-mo -1.85%
3-mo 18.57%
6-mo 0.47%
1-year 32.63%
3-year 140.91%
5-year 6.00%
YTD 6.00%
2021 138.10%
2020 -8.70%
2019 100.17%
2018 -71.55%
2017 -47.55%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6211 seconds.